We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association.
- Authors
Kim, Han Sun; Kim, Doyeon; Kim, Jiwoo; Park, Sunghyouk; de Guzman, Arvie Camille V.
- Abstract
SCD and MTHFD2 inhibitors for high-risk acute myeloid leukaemia patients, as suggested by ELN2017-pathway association Dear Editor, The European LeukemiaNet (ELN) 2017 criteria[1] is widely accepted as the risk classification of acute myeloid leukaemia (AML) patients. Overall, our study identified risk-associated pathways, target genes and potential synergistic drugs with cytarabine in AML through novel bioinformatic analysis on large multiomic datasets. Dose-response curves and IC50s for (A) DS18561882 drug and (B) A939572 drug to five AML cell lines (U937, MOLM-14, THP-1, KG-1 and HL-60) and one normal cell line (HCC1954-BL) by CCK-8 assay.
- Subjects
ACUTE myeloid leukemia; CYTARABINE; FOLIC acid; MONONUCLEAR leukocytes; UNSATURATED fatty acids
- Publication
Clinical & Translational Medicine, 2023, Vol 13, Issue 7, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.1311